NAMS Stock: Price, Earnings History and SEC Filings
NewAmsterdam Pharma Company N.V. (NAMS) last traded at $20.06, down 3.37% on the latest session and down 17.5% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $-0.52 against an analyst estimate of $-0.48, a miss of 8.3%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
NAMS earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 5, 2026 | $-0.52 | $-0.48 | -8.33% |
| Mar 2026 | May 7, 2026 | $-0.40 | $-0.46 | +13.04% |
| Dec 2025 | Feb 18, 2026 | $-0.63 | $-0.40 | -57.50% |
| Sep 2025 | Nov 5, 2025 | $-0.41 | $-0.38 | -7.89% |
NAMS beat the analyst EPS estimate in 1 of its last 4 reported quarters. Source: Nasdaq.
How NAMS reacts to earnings
Across its last 8 earnings releases, NAMS moved 5.4% on average the next session, in either direction. It rose after 6 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-08-05 | Before open | -0.47% |
| 2026-05-07 | Before open | +12.46% |
| 2026-02-18 | Before open | +1.48% |
| 2026-01-09 | Before open | -3.99% |
| 2025-11-05 | Before open | +4.37% |
| 2025-08-06 | Before open | +8.70% |
| 2025-05-08 | Before open | +1.85% |
| 2025-02-26 | Before open | +10.23% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
NAMS financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | $23M | -$204M | – | -905.7% | $-1.72 |
| 2024 | $46M | -$242M | – | -530.3% | $-2.56 |
| 2023 | $14M | -$177M | – | -1255.8% | $-2.15 |
| 2022 | $103M | -$23M | – | -22.0% | $-1.19 |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for NAMS
- 8-K · Sep 29, 2026Other events, Financial statements and exhibits
- 8-K · Sep 21, 2026Other events
- 8-K · Aug 14, 2026Officer or director change
- 8-K · Aug 5, 2026Results of operations, Financial statements and exhibits
- 10-Q · Aug 5, 2026
- 8-K · Jul 24, 2026Other events, Financial statements and exhibits
- 8-K · Jul 22, 2026Officer or director change
- 8-K · Jun 3, 2026Officer or director change, Shareholder vote, Financial statements and exhibits
- 8-K · May 7, 2026Results of operations, Financial statements and exhibits
- 10-Q · May 7, 2026
Insider filing activity
NAMS insiders filed 5 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
NAMS news
No recent headlines found. The live terminal has the full news feed.
About NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Company N.V. (NAMS) is a US-listed public company on Nasdaq. The SEC classifies its business as Pharmaceutical Preparations. It is incorporated in Netherlands. Its fiscal year ends in December.